150 related articles for article (PubMed ID: 11127579)
1. Blockade of TGF-beta by in vivo gene transfer of a soluble TGF-beta type II receptor in the muscle inhibits corneal opacification, edema and angiogenesis.
Sakamoto T; Ueno H; Sonoda K; Hisatomi T; Shimizu K; Ohashi H; Inomata H
Gene Ther; 2000 Nov; 7(22):1915-24. PubMed ID: 11127579
[TBL] [Abstract][Full Text] [Related]
2. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration.
Honda M; Sakamoto T; Ishibashi T; Inomata H; Ueno H
Gene Ther; 2000 Jun; 7(11):978-85. PubMed ID: 10849558
[TBL] [Abstract][Full Text] [Related]
3. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma.
Shiose S; Sakamoto T; Yoshikawa H; Hata Y; Kawano Y; Ishibashi T; Inomata H; Takayama K; Ueno H
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2395-403. PubMed ID: 10937546
[TBL] [Abstract][Full Text] [Related]
4. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.
Takayama K; Ueno H; Nakanishi Y; Sakamoto T; Inoue K; Shimizu K; Oohashi H; Hara N
Cancer Res; 2000 Apr; 60(8):2169-77. PubMed ID: 10786681
[TBL] [Abstract][Full Text] [Related]
5. Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy.
Oshima Y; Sakamoto T; Hisatomi T; Tsutsumi C; Ueno H; Ishibashi T
Gene Ther; 2002 Sep; 9(18):1214-20. PubMed ID: 12215888
[TBL] [Abstract][Full Text] [Related]
6. Catheter-based adenovirus-mediated local intravascular gene delivery of a soluble TGF-beta type II receptor using an infiltrator in porcine coronary arteries: efficacy and complications.
Chung IM; Ueno H; Pak YK; Kim JW; Choi DH; Shin GJ; Yang WI; Jang Ys
Exp Mol Med; 2002 Sep; 34(4):299-307. PubMed ID: 12515396
[TBL] [Abstract][Full Text] [Related]
7. Prevention of radiation-induced pneumonitis by recombinant adenovirus-mediated transferring of soluble TGF-beta type II receptor gene.
Haiping Z; Takayama K; Uchino J; Harada A; Adachi Y; Kura S; Caicun Z; Tsuzuki T; Nakanishi Y
Cancer Gene Ther; 2006 Sep; 13(9):864-72. PubMed ID: 16710346
[TBL] [Abstract][Full Text] [Related]
8. Histopathologic amelioration of fibroproliferative change in rat irradiated lung using soluble transforming growth factor-beta (TGF-beta) receptor mediated by adenoviral vector.
Nishioka A; Ogawa Y; Mima T; Jin YJ; Sonobe H; Kariya S; Kubota K; Yoshida S; Ueno H
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1235-41. PubMed ID: 15001268
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats.
Nakamura T; Sakata R; Ueno T; Sata M; Ueno H
Hepatology; 2000 Aug; 32(2):247-55. PubMed ID: 10915731
[TBL] [Abstract][Full Text] [Related]
10. Modulation of renal glomerular disease using remote delivery of adenoviral-encoded solubletype II TGF-beta receptor fusion molecule.
Haviv YS; Takayama K; Nagi PA; Tousson A; Cook W; Wang M; Lam JT; Naito S; Lei X; Carey DE; Curiel DT
J Gene Med; 2003 Oct; 5(10):839-851. PubMed ID: 14533192
[TBL] [Abstract][Full Text] [Related]
11. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
Ichikura H; Eto M; Ueno H; Harada M; Takayama K; Tokuda N; Tatsugami K; Naito S
Oncol Rep; 2006 May; 15(5):1333-7. PubMed ID: 16596207
[TBL] [Abstract][Full Text] [Related]
12. Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis.
Zhou A; Ueno H; Shimomura M; Tanaka R; Shirakawa T; Nakamura H; Matsuo M; Iijima K
Kidney Int; 2003 Jul; 64(1):92-101. PubMed ID: 12787399
[TBL] [Abstract][Full Text] [Related]
13. [Inhibiting scar formation in rat cutaneous wounds by blocking TGF-beta signaling].
Liu W; Chua CH; Wu XL; Wang DR; Yin DM; Cui L; Cao YL; Longaker MT
Zhonghua Yi Xue Za Zhi; 2003 Jan; 83(1):31-6. PubMed ID: 12757642
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of corneal neovascularization by recombinant adenovirus-mediated sFlk-1 expression.
Yu H; Wu J; Li H; Wang Z; Chen X; Tian Y; Yi M; Ji X; Ma J; Huang Q
Biochem Biophys Res Commun; 2007 Oct; 361(4):946-52. PubMed ID: 17692288
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ.
Vajanto I; Rissanen TT; Rutanen J; Hiltunen MO; Tuomisto TT; Arve K; Närvänen O; Manninen H; Räsänen H; Hippeläinen M; Alhava E; Ylä-Herttuala S
J Gene Med; 2002; 4(4):371-80. PubMed ID: 12124979
[TBL] [Abstract][Full Text] [Related]
17. The gene transfer of soluble VEGF type I receptor (Flt-1) attenuates peritoneal fibrosis formation in mice but not soluble TGF-beta type II receptor gene transfer.
Motomura Y; Kanbayashi H; Khan WI; Deng Y; Blennerhassett PA; Margetts PJ; Gauldie J; Egashira K; Collins SM
Am J Physiol Gastrointest Liver Physiol; 2005 Jan; 288(1):G143-50. PubMed ID: 15297261
[TBL] [Abstract][Full Text] [Related]
18. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
[TBL] [Abstract][Full Text] [Related]
19. Rapid ocular angiogenic control via naked DNA delivery to cornea.
Stechschulte SU; Joussen AM; von Recum HA; Poulaki V; Moromizato Y; Yuan J; D'Amato RJ; Kuo C; Adamis AP
Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):1975-9. PubMed ID: 11481260
[TBL] [Abstract][Full Text] [Related]
20. Application of an adenoviral vector encoding soluble transforming growth factor-beta type II receptor to the treatment of diabetic nephropathy in mice.
Kondo T; Takemura G; Kosai K; Ohno T; Takahashi T; Esaki M; Goto K; Maruyama R; Murata I; Minatoguchi S; Fujiwara T; Fujiwara H
Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1288-93. PubMed ID: 18505441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
